"
Professor Bond made a similar discovery previously with a particular class of beta blockers with regards to the treatment of chronic heart failure, for which beta blockers were con- traindicated. He brought that discovery to Dr Mitchell Glass (now Invion’s Chief Medical Officer) at GlaxoSmithKline. That subset of drugs became the best drugs ever available to decreasing mortality in heart failure, according to Professor Bond. The discovery moved a $40 million selling drug in 1998 to a $1.5 billion dollar drug in 2010.
For the second time Professor Bond has sought to commercialise his work on contraindications of beta blockers through Dr Mitchell Glass, this time through Invion.
"
Bioshares
IVX Price at posting:
0.7¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)